Press Release: SeaStar Medical’s lead product candidate, the Selective |

– The SCD is currently under evaluation by the FDA for Humanitarian Device Exemption (HDE) marketing approval for use in children (>20 kg) with AKI

– The company expects complete the FDA a content review it is HDE application in the first quarter of 2023

DENVER, COLORADO, Nov. 7, 2022 (GLOBE NEWSWIRE) — starfish Medical holding company (Nasdaq:ICU), (“SeaStar Medical” or the “Company”), a medical technology company developing proprietary solutions to reduce the impact of hyper-inflammation on vital organs, today announced that its Selective Cytopheretic Device (SCD) in Consensus Statement on Pediatric Acute Kidney Injury (AKI) as part of the first meeting of the Pediatric Acute Disease Quality Initiative (pADQI). The outcome of the meeting entitled “Consensus-based recommendations on priority activities for treating acute kidney injury in children“, has appeared in JAMA network open¹.

The first pediatric ADQI…